Navigation Links
More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
Date:5/22/2008

(PHILADELPHIA) The more than ten million Americans whove received drug-eluting stents to open their blocked coronary arteries have a bright future, according to new research from the University of Pennsylvania School of Medicine.

The findings, among the first large follow-up studies to show a clear, lifesaving benefit of drug-eluting stents compared to bare metal stents, will be published in the May 27 issue of the Journal of the American College of Cardiology. Patients with the drug-coated stents -- designed not only to open blocked coronary arteries but also to chemically inhibit future blockage -- were less apt to die, have heart attacks or require extra stents or bypass surgery in the two years following placement of the stent.

This might be a hidden nugget of goodness that could not be detected in clinical trials, says Peter W. Groeneveld, MD, MS, assistant professor in Penns Division of General Internal Medicine. There is a distinct possibility that drug-eluting stents not only reduce the need for future cardiac procedures, but also save lives.

Groeneveld and his colleagues studied Medicare data to identify about 72,000 patients who received drug-eluting stents during a nine-month period in 2003, the first year the devices were approved for use in the United States. Overall, the findings showed a clear survival benefit compared to a control group of patients who got bare metal stents -- at 90 days, 1 year and 2 years, patients with drug-coated stents were less likely to die.

In a separate study which will be published in the June issue of the American Heart Journal, Groeneveld also found that drug-eluting stents also offer cost savings during the first year after placement. Although the initial cost of the device averaging $16,000 -- outpaces that of a bare metal stent, which costs about $14,000, the Penn researchers found that among patients with the drug-coated stents, 12 percent of those studied needed additional stents placed in the first year, compared to 15 percent of patients who received bare-metal stents. Few patients in either arm required bypass surgery in the first year following stent placement, but those who received bare-metal stents were twice as likely to need the procedure, leading to an additional cost savings of $714 per patient treated with drug-coated stents. Overall, researchers found that patients with drug-eluting stents each saved an average of $1,350 worth of follow-up care during the year, which projects a total savings of approximately $100 million dollars among the 72,000 drug-eluting stent patients studied.

The researchers note that future studies should focus on how drug therapies including clopidogrel and cholesterol-reducing statin drugs may play a role in outcomes and costs for both types of stent patients. Since recent evidence shows that clopidogrel therapy -- aimed at reducing the risk of blood clots following stent placement -- is an essential step for reducing late drug-eluting stent complications or failure, Groeneveld theorizes that clinical outcomes for drug-eluting stent patients might be boosted even further when patients follow an appropriate long-term drug regimen.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Comparison of obstetric outcomes between on-call and patients own obstetricians
3. Vision restoration therapy shown to improve brain activity in brain injured patients
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
6. Restricting Blood Flow May Help Heart Bypass Patients
7. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
8. Study provides hope that some transplant patients could live free of antirejection drugs
9. Study provides hope that some transplant patients could live free of anti-rejection drugs
10. Longer ambulance journeys boost death risk for seriously ill patients
11. Expenses Overshadow Optimism for Kidney Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... Christie ... an in-kind gift of a VeinViewer® Vision vein finder for the ... to start an IV and draw blood, combining technology with traditional technique. , ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s Day tips ... biography of Rama - Dr. Frederick Lenz. , According to Publisher Roger ... Buddhist teacher for teaching and helping others. Valentine’s Day celebrates love in all ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose ... – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose ... products, garnering increased attention from all stakeholders in the development of new chemical ...
(Date:2/12/2016)... ... 2016 , ... The ThedaCare Center for Healthcare Value is ... April 5-7. The series is a multi-day, multi-workshop event designed to teach leaders ... broad range of topics, including coaching skills, the scientific method of problem solving ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Jones Agency, a ... across eastern Texas, is launching a cooperative charity drive with the Tarrant Area Food ... more than 50,000 individuals and families in need, the Tarrant County Food Bank offers ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
(Date:2/12/2016)... Ky. , Feb. 12, 2016 /PRNewswire/ ... has completed a $47.1 million Series D ... Cormorant Asset Management, Hillhouse Capital Group and ... Morningside Venture Investments, AJU IB Investment, and ... be used to further advance clinical trials ...
(Date:2/11/2016)... -- Stem cells are primitive cells found in all ... capacity to differentiate into mature cell types Stem cells ... mouse embryonic stem cells were derived from embryos in ... first culturing of embryonic stem cells from non-human primates ... 2006 As a result of these discoveries, stem cells ...
Breaking Medicine Technology: